docetaxel anhydrous has been researched along with curcumin in 35 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (curcumin) | Trials (curcumin) | Recent Studies (post-2010) (curcumin) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 16,336 | 593 | 12,705 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (60.00) | 24.3611 |
| 2020's | 14 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arya, GC; Jaitak, V; Kaur, K | 1 |
| Abrial, C; Barthomeuf, C; Bayet-Robert, M; Chollet, P; Durando, X; Gachon, F; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Planchat, E | 1 |
| Choi, HG; Kim, DH; Sung, JH; Yan, YD; Yong, CS | 1 |
| Dai, X; Guo, R; Hou, Z; Xu, H; Xu, Y; Yin, H; Zhang, Z; Zheng, D; Zheng, Y | 1 |
| Choi, HG; Choi, YK; Kim, JO; Marasini, N; Woo, JS; Yan, YD; Yong, CS | 1 |
| Bayet-Robert, M; Morvan, D | 1 |
| Abd Elmageed, ZY; Abdel-Mageed, AB; Kostochka, ML; Liu, X; Mathur, A; Mondal, D; Zhang, H | 1 |
| Liu, S; Tian, C; Wang, H; Wang, Y; Yan, J; Zhang, X | 1 |
| Pawar, H; Suresh, S; Wankhade, SR; Yadav, DK | 1 |
| Gu, D; Hu, L; Hu, Q; Kong, D; Pang, S; Su, J; Xiong, X | 1 |
| Abrial, C; Atger, M; Bayet-Robert, M; Chollet, P; Curé, H; Durando, X; Eymard, JC; Gadea, E; Guy, L; Mahammedi, H; Planchat, E; Pouget, M; Savareux, L; Thivat, E; Van-Praagh, I | 1 |
| Burman, R; Gill, MS; Pawar, H; Singh, C; Surapaneni, SK; Suresh, S; Tikoo, K | 1 |
| Geetha, P; Gopi Mohan, C; Jayakumar, R; Sivaram, AJ | 1 |
| Baishya, R; Bharadwaj, R; Das, MK; Dash, S; Hazarika, H; Loying, P; Sahu, BP | 1 |
| Deng, J; Fan, R; Gao, X; Guo, G; Li, X; Tong, A; You, C; Zhang, X; Zheng, Y; Zhou, L | 1 |
| Chen, X; Guo, C; Li, J; Qiu, Z; Sun, X; Wen, Y; Xing, H; Xu, J; Zhang, Q; Zhao, D; Zheng, Y | 1 |
| Jia, Y; Liu, S; Liu, X; Pan, W; Tian, C; Wang, H; Wang, Y; Yan, J | 1 |
| Banerjee, S; Chowdhury, I; Lillard, JW; Singh, R; Singh, SK | 1 |
| Choi, HG; Hong, SS; Kim, JH; Kim, JK; Kim, JO; Kim, SY; Lim, SJ; Thapa, RK | 1 |
| Chang, C; Chou, F; Lin, C; Luo, J; Niu, Y; Tian, J; Xing, EZ; Yeh, S; Zuo, L | 1 |
| An, Q; Guo, H; Liu, YN; Liu, ZH; Niu, FJ; Shi, CX; Xie, SM; Yang, YY; Zhou, CZ | 1 |
| Ates, H; Cengiz, H; Kocdor, H; Kocdor, MA | 1 |
| Cao, QR; Cui, JH; Lee, BJ; Loebenberg, R; Meghani, N; Park, C | 1 |
| Gao, S; Li, J; Liu, B; Tang, M; Wang, Z; Zhang, L; Zhang, W | 1 |
| Abdul Rahman, MB; Abdulmalek, E; Asmawi, AA; Salim, N | 1 |
| Patel, B; Patel, MM; Rawal, S | 1 |
| Bu, LP; Li, XY; Liu, H; Liu, P; Shao, L; Ying, Q; Yu, SQ | 1 |
| Deng, L; Feng, L; Guo, R; Li, Y; Liu, Z; Qin, L; Yu, Z; Zheng, Y; Zhu, X | 1 |
| Cheng, Y; Hu, Y; Lin, Y; Ran, M; Wang, B; Zheng, S | 1 |
| Abrial, C; Atger, M; Chollet, P; Durando, X; Eymard, JC; Ginzac Couvé, A; Kwiatkowski, F; Mahammedi, H; Monange, B; Passildas-Jahanmohan, J; Pouget, M; Richard, D; Savareux, L; Thivat, E; Van Praagh, I | 1 |
| Deng, L; Fang, Z; Feng, L; Guo, R; Li, Y; Liu, Z; Qin, L; Wu, X; Yu, Z; Zheng, Y; Zhu, X | 1 |
| Tong, L; Wang, G; Wu, C; Zhou, Z | 1 |
| Bensa, V; Celia, C; Cilli, M; Decuzzi, P; Di Francesco, M; Di Francesco, V; Di Marzio, L; Ferreira, M; Fragassi, A; Palange, AL; Pastorino, F; Ponzoni, M | 1 |
| Hu, J; Liu, J; Sun, L; Yao, X; Zhang, Y | 1 |
| Angiolini, V; Bei, R; Benvenuto, M; Di Meo, C; Frajese, GV; Mancini, P; Masuelli, L; Matricardi, P; Nalli, M; Nardozi, D; Paoletti, L; Zoratto, N | 1 |
1 review(s) available for docetaxel anhydrous and curcumin
| Article | Year |
|---|---|
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles | 2021 |
3 trial(s) available for docetaxel anhydrous and curcumin
| Article | Year |
|---|---|
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Curcumin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Time Factors; Treatment Outcome | 2010 |
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromogranin A; Curcumin; Docetaxel; Geriatric Assessment; Humans; Male; Medication Adherence; Middle Aged; Phosphopyruvate Hydratase; Pilot Projects; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Curcumin; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Humans; Male; Medical Futility; Medication Adherence; Middle Aged; Placebos; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2021 |
31 other study(ies) available for docetaxel anhydrous and curcumin
| Article | Year |
|---|---|
Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Chromatography, High Pressure Liquid; Curcumin; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Dose-Response Relationship, Drug; Enzyme Inhibitors; Injections, Intravenous; Male; Rats; Rats, Sprague-Dawley; Substrate Specificity; Taxoids | 2010 |
Synergistic antitumor efficiency of docetaxel and curcumin against lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Curcumin; Docetaxel; Drug Synergism; Female; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Mice; Mice, Nude; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Effect of dose and dosage interval on the oral bioavailability of docetaxel in combination with a curcumin self-emulsifying drug delivery system (SEDDS).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Curcumin; Docetaxel; Drug Delivery Systems; Emulsions; Male; Rats; Rats, Sprague-Dawley; Taxoids | 2012 |
Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Comet Assay; Curcumin; Docetaxel; Female; Glutathione; Glutathione Transferase; Humans; Inflammation; Magnetic Resonance Spectroscopy; MCF-7 Cells; Metabolomics; Multivariate Analysis; Oxidative Stress; Taxoids; Treatment Outcome | 2013 |
Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Curcumin; Docetaxel; Endoplasmic Reticulum Stress; Epithelial Cells; Humans; Male; Mice; Mice, Nude; Nelfinavir; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Taxoids; Thapsigargin | 2014 |
Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Curcumin; Docetaxel; Drug Carriers; Drug Delivery Systems; Heterografts; Humans; Lipids; Male; Mice; Nanomedicine; Particle Size; Polymers; Prostatic Neoplasms; Taxoids | 2016 |
Development and evaluation of co-formulated docetaxel and curcumin biodegradable nanoparticles for parenteral administration.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Curcumin; Docetaxel; Drug Carriers; Drug Evaluation, Preclinical; Female; Humans; Infusions, Parenteral; Male; MCF-7 Cells; Nanoparticles; Random Allocation; Rats; Rats, Wistar; Taxoids | 2016 |
Enhanced antitumor efficacy of folate targeted nanoparticles co-loaded with docetaxel and curcumin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cell Survival; Chemistry, Pharmaceutical; Curcumin; Docetaxel; Drug Carriers; Folic Acid; HeLa Cells; Humans; Lung Neoplasms; Mice, Inbred C57BL; Nanomedicine; Nanoparticles; Polyesters; Polyethylene Glycols; Sarcoma 180; Solubility; Taxoids; Time Factors; Tumor Burden | 2015 |
Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: In vitro evaluation, pharmacokinetic and biodistribution in rats.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Curcumin; Docetaxel; Drug Carriers; Drug Liberation; Female; Folic Acid; Humans; Lipids; MCF-7 Cells; Nanoparticles; Rats; Rats, Wistar; Taxoids; Tissue Distribution | 2016 |
Integration of in silico modeling, prediction by binding energy and experimental approach to study the amorphous chitin nanocarriers for cancer drug delivery.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitin; Curcumin; Docetaxel; Drug Carriers; Fluorouracil; Humans; Molecular Docking Simulation; Nanoparticles; Stomach; Stomach Neoplasms; Taxoids; Thermodynamics | 2016 |
Curcumin-docetaxel co-loaded nanosuspension for enhanced anti-breast cancer activity.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Breast Neoplasms; Curcumin; Docetaxel; Female; Humans; Male; MCF-7 Cells; Mice; Nanoparticles; Particle Size; Solubility; Suspensions; Taxoids; Tissue Distribution | 2016 |
Dual Drug Loaded Biodegradable Nanofibrous Microsphere for Improving Anti-Colon Cancer Activity.
Topics: Abdominal Neoplasms; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Curcumin; Docetaxel; Drug Carriers; Drug Screening Assays, Antitumor; Flow Cytometry; Hemolysis; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Microspheres; Molecular Weight; Nanofibers; Nanoparticles; Neoplasm Metastasis; Poloxamer; Polymers; Spectroscopy, Fourier Transform Infrared; Taxoids; Thermogravimetry; X-Ray Diffraction | 2016 |
Pharmacokinetic effects of curcumin on docetaxel mediated by OATP1B1, OATP1B3 and CYP450s.
Topics: Animals; Antineoplastic Agents; Curcumin; Docetaxel; Drug Interactions; HEK293 Cells; Humans; Kinetics; Liver-Specific Organic Anion Transporter 1; Male; Microsomes, Liver; Organic Anion Transporters, Sodium-Independent; Rats, Sprague-Dawley; Taxoids | 2016 |
Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Topics: Aconitic Acid; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Coumarins; Curcumin; Docetaxel; Drug Delivery Systems; Drug Liberation; Drug Stability; Drug Synergism; Endocytosis; Humans; Inhibitory Concentration 50; Lactic Acid; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Peptides; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prodrugs; Prostatic Neoplasms; Proton Magnetic Resonance Spectroscopy; Taxoids; Thiazoles | 2017 |
Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Curcumin; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2017 |
Role of zein incorporation on hydrophobic drug-loading capacity and colloidal stability of phospholipid nanoparticles.
Topics: Celecoxib; Colloids; Curcumin; Docetaxel; Drug Carriers; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Paclitaxel; Particle Size; Phospholipids; Surface Properties; Zein | 2018 |
Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Curcumin; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Proteolysis; Receptors, Androgen; Tumor Cells, Cultured | 2019 |
Development and characterization of octreotide-modified curcumin plus docetaxel micelles for potential treatment of non-small-cell lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Curcumin; Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Octreotide; Polyethylene Glycols; Polyvinyls | 2019 |
Inhibition of Cancer Stem-Like Phenotype by Curcumin and Deguelin in CAL-62 Anaplastic Thyroid Cancer Cells.
Topics: AC133 Antigen; Apoptosis; Cell Cycle; Cell Line, Tumor; Curcumin; Docetaxel; Drug Therapy, Combination; Humans; Nanog Homeobox Protein; Neoplastic Stem Cells; Octamer Transcription Factors; Oxidative Stress; Phenotype; Rotenone; Superoxide Dismutase; Thy-1 Antigens; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2019 |
Fatty acid chain length impacts nanonizing capacity of albumin-fatty acid nanomicelles: Enhanced physicochemical property and cellular delivery of poorly water-soluble drug.
Topics: A549 Cells; Albumins; Cell Line; Cell Line, Tumor; Curcumin; Docetaxel; Drug Carriers; Drug Liberation; Fatty Acids; HEK293 Cells; Humans; MCF-7 Cells; Micelles; Nanoparticles; Nanotechnology; Particle Size; Solubility; Water | 2020 |
Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Topics: Androgen Receptor Antagonists; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Combined Modality Therapy; Curcumin; Docetaxel; HEK293 Cells; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Lectins, C-Type; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Receptors, Cell Surface; Up-Regulation | 2020 |
Modeling the Effect of Composition on Formation of Aerosolized Nanoemulsion System Encapsulating Docetaxel and Curcumin Using D-Optimal Mixture Experimental Design.
Topics: Aerosols; Antineoplastic Agents; Capsules; Curcumin; Docetaxel; Drug Compounding; Emulsions; Humans; Models, Theoretical; Nanoparticles; Particle Size; Solubility | 2020 |
Fabrication, optimisation and
Topics: Antineoplastic Agents; Calorimetry, Differential Scanning; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cobalt; Curcumin; Docetaxel; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hemolysis; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Lipids; Lung Neoplasms; Microspheres; Nanostructures; Particle Size; Temperature; Tetrazolium Salts; Thiazoles; X-Ray Diffraction | 2020 |
Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadherins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcuma; Curcumin; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pancreatic Neoplasms; Plant Extracts; Poly (ADP-Ribose) Polymerase-1; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2020 |
Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer.
Topics: Animals; Antineoplastic Agents; Curcumin; Docetaxel; Drug Carriers; Drug Liberation; Esophageal Neoplasms; Humans; Hydrogen-Ion Concentration; Nanomedicine; Nanoparticles; Polyethylene Glycols; Polyethyleneimine; Tumor Microenvironment | 2020 |
Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Curcumin; Docetaxel; Drug Carriers; Drug Liberation; Female; Humans; Lactates; Micelles; Ovarian Neoplasms; Polyethylene Glycols | 2020 |
Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chitosan; Curcumin; Docetaxel; Drug Carriers; Drug Liberation; Humans; Hydrogen-Ion Concentration; Lung; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Macrophages; Mice; Myeloid-Derived Suppressor Cells; Nanoparticles; Reactive Oxygen Species; T-Lymphocytes; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
A self-microemulsion enhances oral absorption of docetaxel by inhibiting P-glycoprotein and CYP metabolism.
Topics: Administration, Oral; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Curcumin; Cytochrome P-450 Enzyme System; Docetaxel | 2023 |
Augmented efficacy of nano-formulated docetaxel plus curcumin in orthotopic models of neuroblastoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Child; Curcumin; Docetaxel; Humans; Mice; Nanoparticles; Neuroblastoma; Polymers | 2023 |
Curcumin Enhances the Efficacy of Docetaxel by Promoting Anti-Tumor Immune Response in Head and Neck Squamous Cell Carcinoma.
Topics: Animals; CD8-Positive T-Lymphocytes; Curcumin; Docetaxel; Head and Neck Neoplasms; Humans; Immunity; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2023 |
Hyaluronan-estradiol nanogels as potential drug carriers to target ER+ breast cancer cell line.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Curcumin; Docetaxel; Drug Carriers; Drug Delivery Systems; Estradiol; Female; Humans; Hyaluronic Acid; MCF-7 Cells; Nanogels; Nanoparticles | 2023 |